Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. Show more
Location: Rue Edouard Belin 12, Mont-Saint-Guibert, 1435, Belgium | Website: https://www.nyxoah.com | Industry: Medical Instruments & Supplies | Sector: Healthcare
Market Cap
224.9M
52 Wk Range
$4.34 - $11.87
Previous Close
$5.15
Open
$5.12
Volume
25,520
Day Range
$5.01 - $5.22
Enterprise Value
213.5M
Cash
22.48M
Avg Qtr Burn
-16.98M
Insider Ownership
37.58%
Institutional Own.
22.19%
Qtr Updated
09/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|
